Inhibition of suicidal erythrocyte death by probucol

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 2, 2013, Pages 120-126

  Shaik, Nazneen ^a   Lupescu, Adrian ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

calcium; cell volume; eryptosis; phosphatidylserine; probucol

Indexed keywords

CALCIUM ION; IONOMYCIN; IONOPHORE; LIPOCORTIN 5; PHOSPHATIDYLSERINE; PROBUCOL;

APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL VOLUME; CONTROLLED STUDY; DRUG MECHANISM; ERYPTOSIS; ERYTHROCYTE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING;

ANNEXIN A5; ANTIOXIDANTS; CALCIUM; CELL DEATH; CELL MEMBRANE; CELL SIZE; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FLOW CYTOMETRY; GLUCOSE; HUMANS; OXIDATIVE STRESS; PHOSPHATIDYLSERINES; PROBUCOL;

EID: 84873408200     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182798abc     Document Type: Article

References (75)

1. Tanous D, Hime N, Stocker R. Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds. Redox Rep. 2008;13: 48-59.
2. Yamashita S, Matsuzawa Y. Where are we with probucol: A new life for an old drug? Atherosclerosis. 2009;207:16-23.
3. Aubin MC, Carrier M, Shi YF, et al. Role of probucol on endothelial dysfunction of epicardial coronary arteries associated with left ventricular hypertrophy. J Cardiovasc Pharmacol. 2006;47:702-710.
4. Hong SC, Zhao SP, Wu ZH. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 2006;47:77-81.
5. Van Antwerpen P, Neve J, Moreau P, et al. Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis. J Cardiovasc Pharmacol. 2007;50: 350-351.
6. Gorogawa S, Kajimoto Y, Umayahara Y, et al. Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract. 2002;57:1-10.
7. Li Y, Sheng L, Li W, et al. Probucol attenuates atrial structural remodeling in prolonged pacing-induced atrial fibrillation in dogs. Biochem Biophys Res Commun. 2009;381:198-203.
8. Ruixing Y, Al Ghazali R, Wenwu L, et al. Pretreatment with probucol attenuates cardiomyocyte apoptosis in a rabbit model of ischemia/reperfusion. Scand J Clin Lab Invest. 2006;66:549-558.
9. Sia YT, Lapointe N, Parker TG, et al. Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation. 2002; 105:2549-2555.
10. Walker JR, Sharma A, Lytwyn M, et al. The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity. J Am Soc Echocardiogr. 2011;24:699-705.
11. Chan H, Lougheed M, Laher I, et al. Oxidized low-density lipoprotein inhibits endothelium-dependent vasodilation by an antioxidant-sensitive, lysophosphatidylcholine-independent mechanism. J Cardiovasc Pharmacol. 2003;41:856-865.
12. Oka K, Yasuhara M, Suzumura K, et al. Antioxidants suppress plasma levels of lectinlike oxidized low-density lipoprotein receptor-ligands and reduce atherosclerosis in watanabe heritable hyperlipidemic rabbits. J Cardiovasc Pharmacol. 2006;48:177-183.
13. Zhou SX, Zhou Y, Zhang YL, et al. Antioxidant probucol attenuates myocardial oxidative stress and collagen expressions in post-myocardial infarction rats. J Cardiovasc Pharmacol. 2009;54:154-162.
14. Deng YM, Wu BJ, Witting PK, et al. Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation. 2004;110:1855-1860.
15. Stocker R. Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues. Curr Opin Lipidol. 2009;20:227-235.
16. Li TT, Xie Y, Guo Y, et al. Effect of probucol on vascular remodeling due to atherosclerosis in rabbits: An intravascular ultrasound study. Chin Med J (Engl). 2011;124:1840-1847.
17. Asiri YA. Probucol attenuates cyclophosphamide-induced oxidative apoptosis, p53 and Bax signal expression in rat cardiac tissues. Oxid Med Cell Longev. 2010;3:308-316.
18. Park SY, Lee JH, Kim CD, et al. Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats. Brain Res. 2007;1157:112-120.
19. Su B, Yang YB, Tuo QH, et al. Anti-apoptotic effects of probucol are associated with downregulation of Daxx expression in THP-1 macrophage. Cardiovasc Drugs Ther. 2007;21:37-45.
20. Lang F, Gulbins E, Lerche H, et al. Eryptosis, a window to systemic disease. Cell Physiol Biochem. 2008;22:373-380.
21. Foller M, Sopjani M, Koka S, et al. Regulation of erythrocyte survival by AMP-activated protein kinase. FASEB J. 2009;23:1072-1080.
22. Brugnara C, de Franceschi L, Alper SL. Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest. 1993;92:520-526.
23. Lang PA, Kaiser S, Myssina S, et al. Role of Ca2+-activated K+ channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol. 2003;285: C1553-C1560.
24. Berg CP, Engels IH, Rothbart A, et al. Human mature red blood cells express caspase-3 and caspase-8, but are devoid of mitochondrial regulators of apoptosis. Cell Death Differ. 2001;8:1197-1206.
25. Lang F, Gulbins E, Lang PA, et al. Ceramide in suicidal death of erythrocytes. Cell Physiol Biochem. 2010;26:21-28.
26. Lang KS, Myssina S, Brand V, et al. Involvement of ceramide in hyperosmotic shock-induced death of erythrocytes. Cell Death Differ. 2004; 11:231-243.
27. Klarl BA, Lang PA, Kempe DS, et al. Protein kinase C mediates erythrocyte "programmed cell death" following glucose depletion. Am J Physiol Cell Physiol. 2006;290:C244-C253.
28. Bhavsar SK, Bobbala D, Xuan NT, et al. Stimulation of suicidal erythrocyte death by alpha-lipoic acid. Cell Physiol Biochem. 2010;26:859-868.
29. Foller M, Huber SM, Lang F. Erythrocyte programmed cell death. IUBMB Life. 2008;60:661-668.
30. Foller M, Mahmud H, Gu S, et al. Participation of leukotriene C(4) in the regulation of suicidal erythrocyte death. J Physiol Pharmacol. 2009;60: 135-143.
31. Lau IP, Chen H, Wang J, et al. In vitro effect of CTAB- and PEG-coated gold nanorods on the induction of eryptosis/erythroptosis in human erythrocytes. Nanotoxicology. 2012;6:847-856.
32. Maellaro E, Leoncini S, Moretti D, et al. Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol. 2011. In press.
33. Foller M, Feil S, Ghoreschi K, et al. Anemia and splenomegaly in cGKIdeficient mice. Proc Natl Acad Sci USA. 2008;105:6771-6776.
34. Bhavsar SK, Gu S, Bobbala D, et al. Janus kinase 3 is expressed in erythrocytes, phosphorylated upon energy depletion and involved in the regulation of suicidal erythrocyte death. Cell Physiol Biochem. 2011;27:547-556.
35. Borst O, Abed M, Alesutan I, et al. Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol. 2012;302:C644-C651.
36. Andrews DA, Low PS. Role of red blood cells in thrombosis. Curr Opin Hematol. 1999;6:76-82.
37. Closse C, Dachary-Prigent J, Boisseau MR. Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol. 1999;107:300-302.
38. Gallagher PG, Chang SH, Rettig MP, et al. Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood. 2003;101:4625-4627.
39. Pandolfi A, Di Pietro N, Sirolli V, et al. Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol. 2007;213:699-709.
40. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood. 1996;88:1873-1880.
41. Chung SM, Bae ON, Lim KM, et al. Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol. 2007;27:414-421.
42. Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci. 2005;62:971-988.
43. Nicolay JP, Schneider J, Niemoeller OM, et al. Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem. 2006;18: 223-232.
44. Calderon-Salinas JV, Munoz-Reyes EG, Guerrero-Romero JF, et al. Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease. Mol Cell Biochem. 2011;357:171-179.
45. Myssina S, Huber SM, Birka C, et al. Inhibition of erythrocyte cation channels by erythropoietin. J Am Soc Nephrol. 2003;14:2750-2757.
46. Lang PA, Beringer O, Nicolay JP, et al. Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med. 2006;84:378-388.
47. Kempe DS, Akel A, Lang PA, et al. Suicidal erythrocyte death in sepsis. J Mol Med. 2007;85:273-281.
48. Lang PA, Kasinathan RS, Brand VB, et al. Accelerated clearance of Plasmodium-infected erythrocytes in sickle cell trait and annexin-A7 deficiency. Cell Physiol Biochem. 2009;24:415-428.
49. Siraskar B, Ballal A, Bobbala D, et al. Effect of amphotericin B on parasitemia and survival of plasmodium berghei-infected mice. Cell Physiol Biochem. 2010;26:347-354.
50. Bobbala D, Alesutan I, Foller M, et al. Effect of anandamide in Plasmodium Berghei-infected mice. Cell Physiol Biochem. 2010;26:355-362.
51. Foller M, Bobbala D, Koka S, et al. Suicide for survival - death of infected erythrocytes as a host mechanism to survive malaria. Cell Physiol Biochem. 2009;24:133-140.
52. Koka S, Bobbala D, Lang C, et al. Influence of paclitaxel on parasitemia and survival of Plasmodium berghei infected mice. Cell Physiol Biochem. 2009;23:191-198.
53. Lang PA, Schenck M, Nicolay JP, et al. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med. 2007;13:164-170.
54. Kempe DS, Lang PA, Duranton C, et al. Enhanced programmed cell death of iron-deficient erythrocytes. FASEB J. 2006;20:368-370.
55. Birka C, Lang PA, Kempe DS, et al. Enhanced susceptibility to erythrocyte "apoptosis" following phosphate depletion. Pflugers Arch. 2004; 448:471-477.
56. Zappulla D. Environmental stress, erythrocyte dysfunctions, inflammation, and the metabolic syndrome: Adaptations to CO2 increases? J Cardiometab Syndr. 2008;3:30-34.
57. Felder KM, Hoelzle K, Ritzmann M, et al. Hemotrophic mycoplasmas induce programmed cell death in red blood cells. Cell Physiol Biochem. 2011;27:557-564.
58. Gatidis S, Zelenak C, Fajol A, et al. p38 MAPK activation and function following osmotic shock of erythrocytes. Cell Physiol Biochem. 2011;28: 1279-1286.
59. Ghashghaeinia M, Toulany M, Saki M, et al. The NFkB pathway inhibitors Bay 11-7082 and parthenolide induce programmed cell death in anucleated erythrocytes. Cell Physiol Biochem. 2011;27:45-54.
60. Lang E, Jilani K, Zelenak C, et al. Stimulation of suicidal erythrocyte death by benzethonium. Cell Physiol Biochem. 2011;28:347-354.
61. Nguyen DB, Wagner-Britz L, Maia S, et al. Regulation of phosphatidylserine exposure in red blood cells. Cell Physiol Biochem. 2011;28: 847-856.
62. Qadri SM, Kucherenko Y, Zelenak C, et al. Dicoumarol activates Ca-permeable cation channels triggering erythrocyte cell membrane scrambling. Cell Physiol Biochem. 2011;28:857-864.
63. Qadri SM, Bauer J, Zelenak C, et al. Sphingosine but not sphingosine-1-phosphate stimulates suicidal erythrocyte death. Cell Physiol Biochem. 2011;28:339-346.
64. Bhavsar SK, Eberhard M, Bobbala D, et al. Monensin induced suicidal erythrocyte death. Cell Physiol Biochem. 2010;25:745-752.
65. Braun M, Foller M, Gulbins E, et al. Eryptosis triggered by bismuth. Biometals. 2009;22:453-460.
66. Eberhard M, Ferlinz K, Alizzi K, et al. FTY720-induced suicidal erythrocyte death. Cell Physiol Biochem. 2010;26:761-766.
67. Qian EW, Ge DT, Kong SK. Salidroside protects human erythrocytes against hydrogen peroxide-induced apoptosis. J Nat Prod. 2012;75: 531-537.
68. Shinomiya M, Shirai K, Saito Y, et al. Inhibition of intimal thickening of the carotid artery of rabbits and of outgrowth of explants of aorta by probucol. Atherosclerosis. 1992;97:143-148.
69. Uchiyama H, Tozuka Y, Imono M, et al. Transglycosylated stevia and hesperidin as pharmaceutical excipients: dramatic improvement in drug dissolution and bioavailability. Eur J Pharm Biopharm. 2010;76:238-244.
70. Brand VB, Sandu CD, Duranton C, et al. Dependence of Plasmodium falciparum in vitro growth on the cation permeability of the human host erythrocyte. Cell Physiol Biochem. 2003;13:347-356.
71. Nicolay JP, Liebig G, Niemoeller OM, et al. Inhibition of suicidal erythrocyte death by nitric oxide. Pflugers Arch. 2008;456:293-305.
72. Jiang JL, Li Ns NS, Li YJ, et al. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol. 2002;135:1175-1182.
73. Bookchin RM, Ortiz OE, Lew VL. Activation of calcium-dependent potassium channels in deoxygenated sickled red cells. Prog Clin Biol Res. 1987;240:193-200.
74. Taniguchi T, Uesugi M, Arai T, et al. Chronic probucol treatment decreases the slow component of the delayed-rectifier potassium current in cho cells transfected with KCNQ1 and KCNE1: A novel mechanism of QT prolongation. J Cardiovasc Pharmacol. 2012;59: 377-386.
75. Howland JL, Daughtey JN, Donatelli M, et al. Inhibition of the erythrocyte calcium-sensitive potassium channel by probucol. Pharmacol Res Commun. 1984;16:1057-1064.